The application of an enamel matrix protein derivative (Emdogain®) in regenerative periodontal therapy: A review

Medical Principles and Practice

Volumn 16, Issue 3, 2007, Pages 167-180

  Sculean, Anton ^a   Schwarz, Frank ^b   Becker, Jürgen ^b   Brecx, Michel ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cementogenesis; Emdogain, review; Enamel matrix protein derivative; Regenerative periodontal therapy

Indexed keywords

EMDOGAIN; ENAMEL MATRIX PROTEIN DERIVATIVE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ALVEOLAR BONE; BONE DEFECT; BONE GRAFT; CEMENTUM; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; NONHUMAN; PERIODONTAL LIGAMENT; PERIODONTITIS; REVIEW; SURGICAL WOUND; TISSUE REGENERATION; WOUND HEALING;

ALVEOLAR BONE LOSS; ANIMALS; BONE REGENERATION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DENTAL ENAMEL PROTEINS; GUIDED TISSUE REGENERATION, PERIODONTAL; HUMANS; PERIODONTAL ATTACHMENT LOSS; SURGICAL FLAPS; TOOTH ROOT; WOUND HEALING;

EID: 34147172213     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100386     Document Type: Review

References (140)

1. Hammarström L: Enamel matrix, cementum development and regeneration. J Clin Periodontol 1997;24:658-668.
2. Slavkin HC, Boyde A: Cementum: an epithelial secretory product? J Dent Res 1975;53:157.
3. Slavkin HC: Towards a cellular and molecular understanding of periodontics: cemento-genesis revisited. J Periodontol 1976;47:249-255.
4. Brookes SJ, Robinson C, Kirkham J, Bonass WA: Biochemistry and molecular biology of amelogenin proteins of developing dental enamel. Arch Oral Biol 1995;40:1-4.
5. Gestrelius S, Andersson C, Johansson AC, Persson E, Brodin A, Rydhag L, Hammarström L: Formulation of enamel matrix derivative surface coating: kinetics and cell colonization. J Clin Periodontol 1997;24:678-684.
6. Maycock J, Wood SR, Brookes SJ, Shore RC, Robinson C, Kirkham J: Characterization of a porcine amelogenin preparation, EMDOGAIN, a biologic treatment for periodontal disease. Connect Tissue Res 2002;43:472-476.
7. World Workshop in Periodontology: The American Academy of Periodontology. Ann Periodontol 1996;1:618-670.
8. Gestrelius S, Andersson C, Lidström D, Hammarström L, Sommerman M: In vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodontol 1997;24:685-692.
9. Haase HR, Bartold PM: Enamel matrix derivative induces matrix synthesis by cultured human periodontal fibroblast cells. J Periodontol 2001;72:341-348.
10. Hoang AM, Oates TW, Cochran DL: In vitro wound healing responses to enamel matrix derivative. J Periodontol 2000;71:1270-1277.
11. Hoang AM, Klebe RJ, Steffensen B, Ryu OH, Simmer JP, Cochran DL: Amelogenin is a cell adhesion protein. J Dent Res 2002;81:497-500.
12. Lyngstadaas SP, Lundberg E, Ekdahl H, Andersson C, Gestrelius S: Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative. J Clin Periodontol 2001;28:181-188.
13. Okubo K, Kobayashi M, Takiguchi T, Takada T, Ohazama A, Okamatsu Y, Hasegawa K: Participation of endogenous IGF-I and TGF-beta 1 with enamel matrix derivative-stimulated cell growth in human periodontal ligament cells. J Periodont Res 2003;38:1-9.
14. Palioto DB, Coletta RD, Graner E, Joly JC, de Lima AF: The influence of enamel matrix derivative associated with insulin-like growth factor-I on periodontal ligament fibroblasts. J Periodontol 2004;75:498-504.
15. Kawase T, Okuda K, Momose M, Kato Y, Yoshie H, Burns DM: Enamel matrix derivative (EMDOGAIN) rapidly stimulates phosphorylation of the MAP kinase family and nuclear accumulation of smad2 in both oral epithelial and fibroblastic human cells. J Periodont Res 2001;36, 367-376.
16. Kawase T, Okuda K, Yoshie H, Burns DM: Anti-TGF-beta antibody blocks enamel matrix derivative-induced upregulation of p21WAF1/cip1 and prevents its inhibition of human oral epithelial cell proliferation. J Periodont Res 2002;37:255-262.
17. Suzuki S, Nagano T, Yamakoshi Y, Gomi K, Arai T, Fukae M, Katagiri T, Oida S: Enamel matrix derivative gel stimulates signal transduction of BMP and TGF-β. J Dent Res 2005;84:510-514.
18. Takayama T, Suzuki N, Narukawa M, Tokunaga T, Otsuka K, Ito K: Enamel matrix derivative stimulates core binding factor alpha1/Runt-related transcription factor-2 expression via activation of Smad in C2C12 cells. J Periodontol 2005;76:244-249.
19. Keila S, Nemcovsky CE, Moses O, Artzi Z, Weinreb M: In vitro effects of enamel matrix proteins on rat bone marrow cells and gingival fibroblasts. J Dent Res 2004;83:134-138.
20. Ohyama M, Suzuki N, Yamaguchi Y, Maeno M, Otsuka K, Ito K: Effect of enamel matrix derivative on the differentiation of C2C12 cells. J Periodontol 2002;73:543-550.
21. Van der Pauw MT, Van Den Bos T, Everts V, Beertsen W: Enamel matrix-derived protein stimulates attachment of periodontal ligament fibroblast and enhances alkaline phosphatase activity and transforming growth factor β1 release of periodontal ligament and gingival fibroblasts. J Periodontol 2000;71:31-43.
22. Cattaneo V, Rota C, Silvestri M, Piacentini C, Forlino A, Gallanti A, Rasperini G, Cetta G: Effect of enamel matrix derivative on human periodontal fibroblasts: proliferation, morphology and root surface colonization - an in vitro study. J Periodont Res 2003;38:568-574.
23. Davenport DR, Mailhot JM, Wataha JC, Billman MA, Sharawy MM, Shrout MK: Effects of enamel matrix protein application on the viability, proliferation, and attachment of human periodontal ligament fibroblasts to diseased root surfaces in vitro. J Clin Periodontol 2003;30:125-131.
24. Van der Pauw MT, Everts V, Beertsen W: Expression of integrins by human periodontal ligament and gingival fibroblasts and their involvement in fibroblast adhesion to enamel matrix-derived proteins. J Periodont Res 2002;37:317-323.
25. Tokiyasu Y, Takata T, Saygin E, Somerman MJ: Enamel factors regulate expression of genes associated with cementoblasts. J Periodontol 2000;71:1829-1839.
26. Inoue M, LeGeros RZ, Hoffman C, Diamond K, Rosenberg PA, Craig RG: Effect of enamel matrix proteins on the phenotype expression of periodontal ligament cells cultured on dental materials. J Biomed Mater Res A 2004;69:172-179.
27. Gurpinar A, Onur MA, Cehreli ZC, Tasman F: Effect of enamel matrix derivative on mouse fibroblasts and marrow stromal osteoblasts. J Biomater Appl 2003;18:25-33.
28. Koike Y, Murakami S, Matsuzaka K, Inoue T: The effect of Emdogain on ectopic bone formation in tubes of rat demineralized dentin matrix. J Periodont Res 2005;40:385-394.
29. Baker DL, Stanley Pavlow SA, Wikesjö UM: Fibrin clot adhesion to dentin conditioned with protein constructs: an in vitro proof-of-principle study. J Clin Periodontol 2005;32:561-566.
30. Kawase T, Okuda K, Yoshie H, Burns DM: Cytostatic action of enamel matrix derivative (EMDOGAIN®) on human oral squamous cell carcinoma-derived SCC25 epithelial cells. J Periodont Res 2000;35:291-300.
31. Boyan BD, Weesner TC, Lohmann CH, Andreacchio D, Carnes DL, Dean DD, Cochran DL, Schwarz Z: Porcine fetal enamel matrix derivative enhances bone formation induced by demineralized freeze dried bone allograft in vivo. J Periodontol 2000;71:1278-1286.
32. Schwartz Z, Carnes DL Jr, Pulliam R, Lohmann CH, Sylvia VL, Liu Y, Dean DD, Cochran DL, Boyan BD: Porcine fetal enamel matrix derivative stimulates proliferation but not differentiation of pre-osteoblastic 2T9 cells, inhibits proliferation and stimulates differentiation of osteoblast-like MG63 cells, and increases proliferation and differentiation of normal human osteoblast NHOst cells. J Periodontol 2000;71:1287-1296.
33. Takayanagi K, Osawa G, Nakaya H, Cochran DL, Kamoi K, Oates TW. Effects of enamel matrix derivative on bone-related mRNA expression in human periodontal ligament cells in vitro. J Periodontol 2006;77:891-898.
34. 2 osteoblasts on titanium implants. Clin Oral Investig 2004;8:165-171.
35. Mizutani S, Tsuboi T, Tazoe M, Koshihara Y, Goto S, Togari A: Involvement of FGF-2 in the action of Emdogain on normal human osteoblastic activity. Oral Dis 2003;9:210-217.
36. Matsuda N, Horikawa M, Watanabe M, Kitagawa S, Kudo Y, Takata T: Possible involvement of extracellular signal-regulated kinases 1/2 in mitogenic response of periodontal ligament cells to enamel matrix derivative. Eur J Oral Sci 2002;110:439-444.
37. Hägewald S, Pischon N, Jawor P, Bernimoulin JP, Zimmermann B: Effects of enamel matrix derivative on proliferation and differentiation of primary osteoblasts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:243-249.
38. He J, Jiang J, Safavi KE, Spangberg LS, Zhu Q: Direct contact between enamel matrix derivative (EMD) and osteoblasts is not required for EMD-induced cell proliferation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:370-375.
39. Shimizu E, Nakajima Y, Kato N, Nakayama Y, Saito R, Samoto H, Ogata Y: Regulation of rat bone sialoprotein gene transcription by enamel matrix derivative. J Periodontol 2004;75:260-267.
40. Hattar S, Asselin A, Greenspan D, Oboeuf M, Berdal A, Sautier JM: Potential of biomimetic surfaces to promote in vitro osteoblast-like cell differentiation. Biomaterials 2005;26:839-848.
41. Parkar MH, Tonetti M: Gene expression profiles of periodontal ligament cells treated with enamel matrix proteins in vitro: analysis using cDNA arrays. J Periodontol 2004;75:1539-1546.
42. Sculean A, Auschill TM, Donos N, Brecx M, Arweiler N: Effect of an enamel matrix derivative (EMDOGAIN®) on ex vivo dental plaque vitality. J Clin Periodontol 2001;28:1074-1078.
43. Arweiler NB, Auschill TM, Donos N, Sculean A: Antibacterial effect of an enamel matrix protein derivative on in vivo dental biofilm vitality. Clin Oral Invest 2002;6:205-209.
44. Spahr A, Lyngstadaas SP, Boeckh C, Andersson C, Podbielski A, Haller B: Effect of the enamel matrix derivative EMDOGAIN® on the growth of periodontal pathogens in vitro. J Clin Periodontol 2001;29:62-72.
45. Newman SE, Coscia SA, Jotwani R, Iacono VJ, Cutler CW: Effects of enamel matrix derivative on Porphyromonas gingivalis. J Periodontol 2003;74:1191-1195.
46. Walter C, Jawor P, Bernimoulin JP, Hagewald S: Moderate effect of enamel matrix derivative (EMDOGAIN®) on Porphyromonas gingivalis growth in vitro. Arch Oral Biol 2006;51:171-176.
47. Inaba H, Kawai S, Nakayama K, Okahashi N, Amano A: Effect of enamel matrix derivative on periodontal ligament cells in vitro is diminished by Porphyromonas gingivalis. J Periodontol 2004;75:858-865.
48. Rincon JC, Haase HR, Bartold PM: Effect of Emdogain on human periodontal fibroblasts in an in vitro wound healing model. J Periodont Res 2003;38:290-295.
49. Mirastschijski U, Konrad D, Lundberg E, Lyngstadaas SP, Jorgensen LN, Agren MS: Effects of a topical enamel matrix derivative on skin wound healing. Wound Repair Regen 2004;12:100-108.
50. Yuan K, Chen CL, Lin MT: Enamel matrix derivative exhibits angiogenic effect in vitro and in a murine model. J Clin Periodontol 2003;30:732-738.
51. Myhre AE, Lyngstaadas SP, Dahle MK, Stuestøl JF, Foster SJ, Thiemermann C, Lilleaasen P, Wang JE, Aasen AO: Anti-inflammatory properties of enamel matrix derivative in human blood. J Periodont Res 2006;41:208-213.
52. Takayama T, Suzuki N, Narukawa M, Goldberg HA, Otsuka K, Ito K: Enamel matrix derivative is a potent inhibitor of breast cancer cell attachment to bone. Life Sci 2005;76:1211-1221.
53. Hamamoto Y, Kawasaki N, Jarnbring F, Hammarström L: Effects and distribution of the enamel matrix derivative Emdogain in the periodontal tissues of rat molars transplanted to the abdominal wall. Dent Traumatol 2002;18:12-33.
54. Onodera H, Shibukawa Y, Sugito H, Ota M, Yamada S: Periodontal regeneration in intrabony defects after application of enamel matrix proteins with guided tissue regeneration: an experimental study in dogs. Biomed Res 2005;26:69-77.
55. Chano L, Tenenbaum HC, Lekic PC, Sodek J, McCulloch CA: Emdogain regulation of cellular differentiation in wounded rat periodontium. J Periodont Res 2003;38:164-174.
56. Hammarström L, Heijl L, Gestrelius S: Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 1997;24:669-677.
57. Sculean A, Donos N, Brecx M, Karring T, Reich E: Healing of fenestration-type defects following treatment with guided tissue regeneration or enamel matrix proteins: an experimental study in monkeys. Clin Oral Invest 2000;4:50-56.
58. Sculean A, Donos N, Reich E, Brecx M, Karring T: Healing of recession-type defects following treatment with enamel matrix proteins or guided tissue regeneration: a pilot study in monkeys. J Parodontol Implant Orale 2000;19:19-31.
59. Sculean A, Donos N, Brecx M, Reich E, Karring T: Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration: an experimental study in monkeys. J Clin Periodontol 2000;27:466-472.
60. Sakallioglu U, Acikgoz G, Ayas B, Kirtiloglu T, Sakallioglu E: Healing of periodontal defects treated with enamel matrix proteins and root surface conditioning - and experimental study in dogs. Biomaterials 2004;25:1831-1840.
61. Nemcowsky CE, Zahavi S, Moses O, Kebudi E, Artzi Z, Beny L, Weinreb M: Effect of enamel matrix protein derivative on healing of surgical supra-infrabony periodontal defects in the rat molar: a histomorphometric study. J Periodontol 2006;77:996-1002.
62. Sallum EA, Casati MZ, Caffesse RG, Funis LP, Nociti Junior FH, Sallum AW: Coronally positioned flap with or without enamel matrix protein derivative for the treatment of gingival recessions. Am J Dent 2003;16:287-291.
63. Sallum EA, Pimentel SP, Saldanha JB, Nogueira-Filho GR, Casati MZ, Nociti FH, Sallum AW: Enamel matrix derivative and guided tissue regeneration in the treatment of dehiscence-type defects: a histomorphometric study in dogs. J Periodontol 2004;75:1357-1363.
64. Cochran DL, King GN, Schoolfield J, Velasquez-Plata D, Mellonig JT, Jones A: The effect of enamel matrix proteins on periodontal regeneration as determined by histological analyses. J Periodontol 2003;74:1043-1055.
65. Regazzini PF, Novaes AB Jr, de Oliveira PT, Palioto DB, Taba M Jr, de Souza SL, Grisi MF: Comparative study of enamel matrix derivative with or without GTR in the treatment of class I furcation lesions in dogs. Int J Periodontics Restorative Dent 2004;24:476-487.
66. Donos N, Sculean A, Glavind L, Reich E, Karring T: Wound healing of degree III furcation involvements following guided tissue regeneration and/or Emdogain: a histologic study. J Clin Periodontol 2003;30:1061-1068.
67. Heijl L: Periodontal regeneration with enamel matrix derivative in one human experimental defect: a case report. J Clin Periodontol 1997;24:693-696.
68. Yukna RA, Mellonig J: Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative: a 10-case series. J Periodontol 2000;71:752-759.
69. Sculean A, Donos N, Windisch P, Gera I, Brecx M, Reich E: Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. J Periodont Res 1999;34:310-322.
70. Mellonig JT: Enamel matrix derivative for periodontal reconstructive surgery: technique and clinical and histologic case report. Int J Periodontics Restorative Dent 1999;19:9-19.
71. Sculean A, Chiantella GC, Windisch P, Donos N: Clinical and histologic evaluation of treatment of intrabony defects with an enamel matrix protein derivative (Emdogain®). Int J Periodontics Restorative Dent 2000;20:375-381.
72. Mazjoub Z, Bobbo M, Atiyeh F, Cordioli G: Two patterns of histologic healing in an intrabony defect following treatment with an enamel matrix derivative: a human case report. Int J Periodontics Restorative Dent 2005;25:283-294.
73. Rasperini G, Silvestri M, Schenk RK, Nevins ML: Clinical and histological evaluation of human gingival recession treated with a subepithelial connective tissue graft and enamel matrix derivative (Emdogain): a case report. Int J Periodontics Restorative Dent 2000;20:269-275.
74. Carnio J, Camargo PM, Kenney EB, Schenk RK: Histological evaluation of 4 cases of root coverage following a connective tissue graft combined with an enamel matrix derivative preparation. J Periodontol 2002;73:1534-1543.
75. McGuire MK, Cochran DL: Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. 2. Histological evaluation. J Periodontol 2003;74:1126-1135.
76. Sculean A, Windisch P, Keglevich T, Fabi B, Lundgren E, Lyngstadaas PS: Presence of an enamel matrix protein derivative on human teeth following periodontal surgery. Clin Oral Invest 2002;6:183-187.
77. Sculean A, Junker R, Donos N, Windisch P, Brecx M, Dünker N: Immunohistochemical evaluation of matrix molecules associated with wound healing following treatment with an enamel matrix protein derivative in humans. Clin Oral Invest 2003;7:167-174.
78. Sculean A, Berakdar M, Windisch P, Remberger K, Donos N, Brecx M: Immunohistochemical investigation on the pattern of vimentin expression in regenerated and intact monkey and human periodontal ligament. Arch Oral Biol 2003;2003;48:77-86.
79. Bosshardt DD, Sculean A, Windisch P, Pjetursson BE, Lang NP: Effects of enamel matrix proteins on tissue formation along the roots of human teeth. J Periodont Res 2005;40:158-167.
80. Bosshardt DD, Sculean A, Donos N, Lang NP: Pattern of mineralization after periodontal tissue engineering with enamel matrix proteins. Eur J Oral Sci 2006;114(suppl 1):225-231.
81. St George G, Darbar U, Thomas G: Inflammatory external root resorption following surgical treatment for intra-bony defects: a report of two cases involving EMDOGAIN® and a review of the literature. J Clin Periodontol 2006;33:449-454.
82. Sculean A, Windisch P, Keglevich T, Gera I: Histologic evaluation of human intrabony defects following non-surgical periodontal therapy with and without application of an enamel matrix protein derivative. J Periodontol 2003;74:153-160.
83. Wennström JL, Lindhe J: Some effects of enamel matrix proteins on wound healing in the dento-gingival region. J Clin Periodontol 2002;29:9-14.
84. Hagenaars S, Louwerse PH, Timmerman MF, Van der Velden U, Van der Weijden GA: Soft-tissue wound healing following periodontal surgery and Emdogain application. J Clin Periodontol 2004;31:850-856.
85. Okuda K, Miyazaki A, Momose M, Murata M, Nomura T, Kubota T, Wolff LF, Yosie H: Levels of tissue inhibitor of metalloproteinases-1 and matrix metalloproteinases-1 and -8 in gingival crevicular fluid following treatment with enamel matrix derivative (EMDOGAIN). J Periodont Res 2001;36:309-316.
86. Gutierrez MA, Mellonig JT, Cochran DL: Evaluation of enamel matrix derivative as an adjunct to non-surgical periodontal therapy. J Clin Periodontol 2003;30:739-745.
87. Mombelli A, Brochut P, Plagnat D, Casagni F, Giannopoulou C: Enamel matrix proteins and systemic antibiotics as adjuncts to non-surgical periodontal treatment: clinical effects. J Clin Periodontol 2005;32:225-230.
88. Petinaki E, Nikolopoulos S, Castanas E: Low stimulation of peripheral lymphocytes, following in vitro application of Emdogain. J Clin Periodontol 1998;25:715-720.
89. Nikolopoulos S, Petinaki E, Castanas E: Immunologic effects of Emdogain in humans: one-year results. Int J Periodontics Restorative Dent 2002;22:269-277.
90. Zetterström O, Andersson C, Eriksson L, Frederiksson A, Friskopp J, Heden G, Janssson B, Lundgren T, Nilveus R, Olsson A, Renvert S, Salonen L, Sjöström L, Winell A, Östgren A, Gestrelius S: Clinical safety of enamel matrix derivative (EMDOGAIN®) in the treatment of periodontal defects. J Clin Periodontol 1997;24:697-704.
91. Froum S, Weinberg M, Novak J, Mailhot J, Mellonig J, Van Dyke T, McClain P, Papapanou PN, Childers G, Ciancio S, Blieden T, Polson A, Greenstein G, Yukna R, Wallace ML, Patters M, Wagener C: A multicenter study evaluating the sensitization potential of enamel matrix derivative after treatment of two intrabony defects. J Periodontol 2004;75:1001-1008.
92. Heijl L, Heden G, Svardström G, Östgren A: Enamel matrix derivative (EMDOGAIN®) in the treatment of intrabony periodontal defects. J Clin Periodontol 1997;24:705-714.
93. Froum SJ, Weinberg MA, Rosenberg E, Tarnow D: A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12-month re-entry study. J Periodontol 2001;72:25-34.
94. Pontoriero R, Wennström J, Lindhe J: The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects: a prospective controlled clinical study. J Clin Periodontol 1999;26:833-840.
95. Tonetti MS, Lang NP, Cortellini P, Suvan JE, Adriaens P, Dubravec D, Fonzar A, Fourmousis I, Mayfield L, Rossi R, Silvestri M, Tiedemann C, Topoll H, Vangsted T, Wallkamm B: Enamel matrix proteins in the regenerative therapy of deep intrabony defects: a multicenter randomized controlled clinical trial. J Clin Periodontol 2002;29:317-325.
96. Rösing CK, Aass AM, Mavropoulos A, Gjermo P: Clinical and radiographic effects of enamel matrix derivative in the treatment of intrabony periodontal defects: a 12-month longitudinal placebo-controlled clinical trial in adult periodontitis patients. J Periodontol 2005;76:129-133.
97. Okuda K, Momose M, Miyazaki A, Murata M, Yokohama S, Yonezawa Y, Wolff LF, Yoshie H: Enamel matrix derivative in the treatment of human intrabony osseous defects. J Periodontol 2000;71:1821-1828.
98. Silvestri M, Ricci G, Rasperini G, Sartori S, Cattaneo V: Comparison of treatments of intrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap: a pilot study. J Clin Periodontol 2000;27:603-610.
99. Sculean A, Windisch P, Chiantella GC, Donos N, Brecx M, Reich E: Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration: a prospective controlled clinical study. J Clin Periodontol 2001;28:397-403.
100. Zuchelli G, Bernardi F, Montebugnoli L, De Sanctis: Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol 2002;73:3-12.
101. Silvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V: Comparison of intarbony defects treated with enamel matrix derivative versus guided tissue regeneration with a nonresorbable membrane. J Clin Periodontol 2003;30:386-393.
102. Wachtel H, Schenk G, Bohm S, Weng D, Zuhr O, Hurzeler MB: Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. J Clin Periodontol 2003;30:496-504.
103. Yilmaz S, Kuru B, Altuna-Kirac E: Enamel matrix proteins in the treatment of periodontal sites with horizontal type of bone loss. J Clin Periodontol 2003;30:197-206.
104. Tonetti MS, Fourmousis I, Sauvan J, Cortellini P, Brägger U, Lang NP: Healing, postoperative morbidity and patient perception of outcomes following regenerative therapy of deep intrabony defects. J Clin Periodontol 2004;31:1092-1098.
105. Sculean B, Blaes A, Arweiler N, Reich E, Donos N, Brecx M: The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins. J Periodontol 2001;72:190-195.
106. Sculean A, Berakdar M, Donos N, Auschill TM, Arweiler NB: The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. Clin Oral Invest 2003;7:108-112.
107. Parashis AO, Tsiklakis K, Tatakis DN: EDTA gel root conditioning: lack of effect on clinical and radiographic outcomes of intrabony defect treatment with enamel matrix derivative. J Periodontol 2006;77:103-110.
108. Sculean A, Berakdar M, Willershausen B, Arweiler NB, Becker J, Schwarz F: Effect of EDTA root conditioning on the healing of intrabony defects treated with an enamel matrix protein derivative. J Periodontol 2006;77:1167-1172.
109. Sculean A, Donos N, Blaes A, Lauermann M, Reich E, Brecx M: Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects: a split-mouth study. J Periodontol 1999;70:255-262.
110. Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H, Rasperini G, Merli M, Cortellini P, Sauvan JE: Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial. J Periodontol 2004;75:726-733.
111. Francetti L, Del Fabro M, Basso M, Testori T, Weinstein R: Enamel matrix proteins in the treatment of intra-bony defects: a prospective 24-month clinical trial. J Clin Periodontol 2004;31:52-59.
112. Francetti L, Trombelli L, Lombardo G, Guida L, Cafiero C, Roccuzzo M, Carusi G, Del Fabro M: Evaluation of efficacy of enamel matrix derivative in the treatment of intrabony defects: a 24-month multicenter study. Int J Periodontics Restorative Dent 2005;25:461-473.
113. Sculean A, Donos N, Miliauskaite A, Arweiler N, Brecx M: Treatment of intrabony defects with enamel matrix proteins or bioresorbable membranes: a four-year followup split-mouth study. J Periodontol 2001;72:1695-1701.
114. Sculean A, Donos N, Schwarz F, Becker J, Brecx M, Arweiler NB: Five-year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol 2004;31:545-549.
115. Wikesjö UME, Selvig KA: Periodontal wound healing and regeneration. Periodontol 2000 1999;19:21-39.
116. Tonetti MS, Pini Prato G, Cortellini P: Factors affecting the healing response of intrabony defects following guided tissue regeneration and access flap surgery. J Clin Periodontol 1996;23:548-556.
117. Minabe M, Kodama T, Kogou T, Takeuchi K, Fushimi H, Sugiyama T, Mitarai E: A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects. Int J Periodontics Restorative Dent 2002;22:595-605.
118. Sipos PM, Loos BG, Abbas F, Timmerman MF, van der Velden U: The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. J Clin Periodontol 2005;32:765-772.
119. Sculean A, Windisch P, Keglevich T, Chiantella GC, Gera I, Donos N: Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative combined with a bovine-derived xenograft. Int J Periodontics Restorative Dent 2003;23:47-55.
120. Sculean A, Windisch P, Keglevich T, Gera I: Clinical and histological evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. Int J Periodontics Restorative Dent 2005;25:139-147.
121. Lekovic V, Camargo PM, Weinlaender M, Nedic M, Aleksic Z, Kenney BE: A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intra-bony periodontal defects in humans. J Periodontol 2000;71:1695-1701.
122. Velasquez-Plata D, Scheyer ET, Mellonig JT: Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. J Periodontol 2002;73:433-440.
123. Zucchelli G, Amore C, Montebugnoli L, De Sanctis M: Enamel matrix proteins and bovine porous mineral in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol 2003;74:1725-1735.
124. Gurinsky BS, Mills MP, Mellonig JT: Clinical evaluation of demineralized freezedried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. J Periodontol 2004;75:1309-1318.
125. Sculean A, Pietruska M, Schwarz F, Willershausen B, Arweiler NB, Auschill TM: Healing of human intrabony defects following regenerative periodontal therapy with an enamel matrix protein derivative alone or combined with a bioactive glass: a controlled clinical study. J Clin Periodontol 2005;32:111-117.
126. Sculean A, BarbéG, Chiantella GC, Arweiler NB, Berakdar M, Brecx M: Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. J Periodontol 2002;73:401-408.
127. Sculean A, Chiantella GC, Windisch P, Gera I, Reich E: Clinical evaluation of an enamel matrix protein derivative (Emdogain®) combined with a bovine derived xenograft (Bio-Oss®) for the treatment of intrabony periodontal defects in humans. Int J Periodontics Restorative Dent 2002;22:259-267.
128. Scheyer ET, Velasquez-Plata D, Brunsvold MA, Lasho DJ, Mellonig JT: A clinical comparison of a bovine-derived xenograft used alone and in combination with enamel matrix derivative for the treatment of periodontal osseous defects in humans. J Periodontol 2002;73:423-432.
129. Modica F, Del Pizzo M, Roccuzzo M, Romagnoli R: Coronally advanced flap for the treatment of buccal gingival recessions with and without enamel matrix derivative: a split-mouth study. J Periodontol 2000;71:1693-1698.
130. Hägewald S, Spahr A, Rompola E, Haller B, Heijl L, Bernimoulin JP: Comparative study of EMDOGAIN® and coronally advanced flap technique in the treatment of human gingival recessions: a prospective controlled clinical study. J Clin Periodontol 2002;29:35-41.
131. Spahr A, Hägewald S, Tsoulfidou F, Rompola E, Heijl L, Bernimoulin JP, Ring C, Sander S, Haller B: Coverage of Miller class I and II recession defects using enamel matrix proteins versus coronally repositioned flap technique: a 2-year report. J Periodontol 2005;76:1871-1880.
132. Cueva MA, Boltchi FE, Hallmon WW, Nunn ME, Rivera-Hidalgo F, Rees T: A comparative study of coronally advanced flaps with and without the addition of enamel matrix derivative in the treatment of marginal tissue recession. J Periodontol 2004;75:949-956.
133. Castellanos AT, de la Rosa MR, de la Garza M, Caffesse RG: Enamel matrix derivative and coronal flaps to cover marginal tissue recessions. J Periodontol 2006;77:7-14.
134. McGuire MK, Nunn M: Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. 1. Comparison of clinical parameters. J Periodontol 2003;74:1110-1125.
135. Nemcovsky CE, Artzi Z, Tal H, Kozlovsky A, Moses O: A multicenter comparative study of two root coverage procedures: coronally advanced flap with addition of enamel matrix proteins and subpedicle connective tissue graft. J Periodontol 2004;75:600-607.
136. Berlucchi I, Franchetti L, Del Fabro M, Testori T, Weinstein RL: Enamel matrix proteins (Emdogain) in combination with coronally advanced flap or subepithelial connective tissue graft in the treatment of shallow gingival recessions. Int J Periodontics Restorative Dent 2002;22:583-593.
137. Del Pizzo M, Zucchelli G, Modica F, Villa R, Debernardi C: Coronally advanced flap with or without enamel matrix derivative for root coverage: a 2-year study. J Clin Periodontol 2005;32:1181-1187.
138. Moses O, Artzi Z, Sculean A, Tal H, Kozlovsky A, Romanos GE, Nemcovsky CE: Comparative study of 2 root coverage procedures: a 24-month follow-up multicenter study. J Periodontol 2006;77:195-202.
139. Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, Reich E, Sculean A, Gonzalez JR, Bodeker RH, Meyle J: A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. I. Study design and results for primary outcomes. J Periodontol 2004;75:1150-1160.
140. Meyle J, Gonzalez JR, Bodeker RH, Hoffmann T, Richter S, Heinz B, Arjomand M, Reich E, Sculean A, Jepsen K, Jepsen S: A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. II. Secondary outcomes. J Periodontol 2004;75:1188-1195.